ISSAR Pharma

Home       Therapeutic Areas      Bone and Joints

We are focussing on evolution of science to bring forward a novel peptide therapy for one of the highest contributors of pain and physical disability worldwide: Rheumatoid arthritis

ISSAR has developed a novel synthetic peptide therapeutically targeting joints, which is currently under preclinical trials. We are hoping to improve the quality of life for patients suffering with Rheumatoid arthritis in the near future.

Bones and Joints

The WHO and UN have recognized four major musculoskeletal conditions contributing to a major burden on individuals and health care systems across the world. These include osteoarthritis, rheumatoid arthritis, osteoporosis and lower back pain.

These conditions result in chronic pain and long-lasting physical disability in the affected population. The prevalence and incidence of these conditions increases with age, lifestyle and other physical aspects.

Our Work In Bones and Joints

Our Focused Therapies